AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma

(2009) N Raje et al.   LEUKEMIA

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

(2009) M. S. Squires et al.   MOLECULAR CANCER THERAPEUTICS

Glycogen Synthase Kinase 3  Regulates Cell Death Induced by Synthetic Triterpenoids

(2008) R. Vene et al.   CANCER RESEARCH

A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model

(2008) E. Menu et al.   CANCER RESEARCH

Progress in the evaluation of CDK inhibitors as anti-tumor agents

(2008) C MCINNES   DRUG DISCOVERY TODAY

Identification ofN-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design†

(2008) Paul G. Wyatt et al.   JOURNAL OF MEDICINAL CHEMISTRY

The oral protein-kinase Cβinhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines

(2008) Antonino Neri et al.   LEUKEMIA & LYMPHOMA

Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy

(2008) Zhong Wang et al.   NATURE